Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 5:55 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 457–480 of 5,229 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control/Placebo group Clear all

Conditions: Parkinson Disease
Interventions: Isradipine, Placebo (for Isradipine); Drug
Lead sponsor: University of Rochester; Other
Eligibility: 30 Years and older
Enrollment: 336 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 47
States / cities: Birmingham, Alabama • Sun City, Arizona • Fountain Valley, California + 40 more

Conditions: Arnica, Third Molar Extraction
Interventions: SinEcch, Placebo; Drug · Other
Lead sponsor: Tufts University; Other
Eligibility: 18 Years to 40 Years
Enrollment: 53 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Low Back Pain
Interventions: Fasinumab, placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 35 Years and older
Enrollment: 563 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 58
States / cities: Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 55 more

Conditions: Asthma
Interventions: Daclizumab; Drug
Lead sponsor: Facet Biotech; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2003
U.S. locations: 18
States / cities: Long Beach, California • Mission Viejo, California • San Diego, California + 14 more

Conditions: Onychomycosis
Interventions: Albaconazole 100mg, Albaconazole 200mg, Albaconazole 400mg, Placebo 400 mg; Drug
Lead sponsor: Stiefel, a GSK Company; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 582 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 29
States / cities: Birmingham, Alabama • Tucson, Arizona • Beverly Hills, California + 25 more

Conditions: Endometriosis
Interventions: OG-6219, Placebo; Drug
Lead sponsor: Organon and Co; Industry
Eligibility: 18 Years to 49 Years · Female only
Enrollment: 354 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 27
States / cities: Birmingham, Alabama • Los Angeles, California • Orange, Connecticut + 22 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Exercise-specific self-efficacy, Gentle chair exercise, upper body strength training; Behavioral
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 45 Years and older
Enrollment: 208 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Hepatitis B, Infectious Disease, Liver Diseases
Interventions: CRV431, Placebo, TDF; Drug
Lead sponsor: Hepion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 92 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 3
States / cities: Tempe, Arizona • Lincoln, Nebraska • San Antonio, Texas

Conditions: Dyslipidemia
Interventions: BMS-823778, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 6
States / cities: Little Rock, Arkansas • Lenexa, Kansas • Cincinnati, Ohio + 3 more

Conditions: Diabetes Mellitus, Type 2
Interventions: placebo, linagliptin; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 60 Years and older
Enrollment: 302 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 38
States / cities: Sheffield, Alabama • Chula Vista, California • Costa Mesa, California + 32 more

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: Natalizumab, Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 1,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 72
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 59 more

Conditions: Obesity
Interventions: Tradipitant, Placebo; Drug
Lead sponsor: Vanda Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 3
States / cities: Los Angeles, California • Rochester, Minnesota • New York, New York

Conditions: Down Syndrome
Interventions: Placebo, RO5186582; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 6 Years to 11 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 9
States / cities: Phoenix, Arizona • Decatur, Georgia • Chicago, Illinois + 5 more

Conditions: Healthy Volunteers, Safety After Oral Intake
Interventions: Energy Drink A + Placebo Capsule, Placebo Drink + Moxifloxacin Capsule, Placebo Drink + Caffeine Capsule, Placebo Drink + Placebo Capsule, Energy Drink B, Control Product + Taurine, Control Product + Caffeine + Taurine, Lower Dose Energy Drink A; Dietary Supplement · Drug · Other
Lead sponsor: University of the Pacific; Other
Eligibility: 18 Years to 40 Years
Enrollment: 3 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Stockton, California

Conditions: Diabetic Neuropathy
Interventions: SPM 927; Drug
Lead sponsor: UCB Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 496 participants
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: RTP, North Carolina

Conditions: Idiopathic Pulmonary Fibrosis, Pulmonary Hypertension
Interventions: Ambrisentan, Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 35 Years to 80 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 51
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Davis, California + 40 more

Conditions: Onychomycosis
Interventions: Laser Treatment (Pulsed Nd:YAG 1064 nm Laser); Device
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Stanford, California

Conditions: Anxiety, Chemotherapy-induced Nausea and Vomiting
Interventions: Essential oils, Placebo; Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 100 Years
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Osteoarthritis (OA)
Interventions: GID SVF-2, Placebo; Device · Other
Lead sponsor: GID BIO, Inc.; Industry
Eligibility: 40 Years to 75 Years
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 3
States / cities: Camden, New Jersey • Egg Harbor, New Jersey • San Antonio, Texas

Conditions: Total Knee Arthroplasty Postoperative Pain, Opioid Reduction After TKA
Interventions: NEUROCUPLE™ Patch, Sham patch, Enhanced Recovery After Surgery (ERAS) Standard of Care; Device · Other
Lead sponsor: Jacques E. Chelly; Other
Eligibility: 18 Years and older
Enrollment: 274 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 3
States / cities: Pittsburgh, Pennsylvania

Conditions: Type 1 Diabetes, Obesity, Overweight
Interventions: Tirzepatide, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 905 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 31
States / cities: Santa Barbara, California • Santa Clarita, California • Aurora, Colorado + 27 more

Conditions: Crohn Disease
Interventions: Icotrokinra, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 1,092 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 64
States / cities: Chandler, Arizona • Litchfield Park, Arizona • Scottsdale, Arizona + 51 more

Conditions: Postherpetic Neuralgia, Diabetic Neuropathy, Complex Regional Pain Syndrome, Carpal Tunnel Syndrome, HIV Neuropathy, Idiopathic Sensory Neuropathy, Peripheral Neuropathy
Interventions: Placebo Capsules + Placebo Patch, Placebo capsules + Lidoderm®, Gabapentin + Placebo, Gabapentin + Lidoderm®, Gabapentin 300 mg capsules 1800 mg/day + placebo patch, Gabapentin 1800 mg/day + Lidoderm patch; Drug
Lead sponsor: Endo USA Inc., a Keenova Therapeutics Company; Industry
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 7
States / cities: Birmingham, Alabama • Hueytown, Alabama • Phoenix, Arizona + 4 more

Conditions: Blood Pressure
Interventions: Potassium Chloride, Placebo; Dietary Supplement · Other
Lead sponsor: Tulane University; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: New Orleans, Louisiana

Search by objective public record fields.

Efficacy of Isradipine in Early Parkinson Disease

Efficacy of Arnica Montana in Reducing Postoperative Edema and Pain

A Study to Determine the Efficacy and Safety of Fasinumab for the Treatment of Adults With Chronic Low Back Pain

Study of Daclizumab in Patients With Chronic, Persistent Asthma

Efficacy and Safety Study of 4 Dose Regimens of Oral Albaconazole in Subjects With Distal Subungual Onychomycosis

A Study to Investigate Efficacy and Safety of OG-6219 BID in 3 Dose Levels Compared With Placebo in Participants Aged 18 to 49 With Moderate to Severe Endometriosis-related Pain

Nurse Managed Upper Body Strength Training in Chronic Obstructive Pulmonary Disease (COPD)

A Study in Healthy Volunteers

Safety Study of BMS-823778 in Subjects With Hypercholesterolemia

Linagliptin as Add on to Basal Insulin in the Elderly

Safety and Efficacy of Natalizumab in Combination With Avonex in the Treatment of Multiple Sclerosis

A Study to Measure the Effects of Using Tradipitant on Nausea and Vomiting After GLP-1R Agonist Use

A Study of RO5186582 in Down Syndrome Among Children 6 to 11 Years of Age

Effects of Energy Drinks on Cardiovascular Endpoints

A Trial to Assess the Efficacy and Safety of SPM 927 in Subjects With Painful Distal Diabetic Neuropathy

ARTEMIS-PH - Study of Ambrisentan in Subjects With Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis

Treatment of Onychomycosis Using a 0.65 Millisecond Pulsed Nd:YAG 1064 nm Laser

Use of Aromatherapy to Reduce Symptom Burden

Adipose-derived SVF for the Treatment of Knee OA

NEUROCUPLE™ as an Opioid Alternative Following Total Knee Arthroplasty

A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight

A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease

A Study Of Lidocaine Patch 5% Alone, Gabapentin Alone, And Lidocaine Patch 5% And Gabapentin In Combination For The Relief Of Pain In Patients With Diverse Peripheral Neuropathic Pain Conditions

Potassium Intake-response Trial to Control Hypertension